© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
RSV D486N-mut. fusion protein inh.
oral antiviral clinical candidate
from lower barrier to atropisomerism of lead
Bioorg. Med. Chem., Oct. 31, 2020
Taisho Pharmaceutical, Saitama, JP
“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.